Patents by Inventor Michael Pratta

Michael Pratta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIOMARKERS FOR GRAFT-VERSUS-HOST DISEASE
    Publication number: 20230027606
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.
    Type: Application
    Filed: May 20, 2022
    Publication date: January 26, 2023
    Inventors: Michael D. Howell, Hao Liu, Michael A. Pratta
  • Biomarkers for graft-versus-host disease
    Patent number: 11372003
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: June 28, 2022
    Assignee: Incyte Corporation
    Inventors: Michael D. Howell, Hao Liu, Michael A. Pratta
  • BIOMARKERS FOR GRAFT-VERSUS-HOST DISEASE
    Publication number: 20210123930
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.
    Type: Application
    Filed: October 8, 2020
    Publication date: April 29, 2021
    Inventors: Michael D. Howell, Sherry Owens, Michael A. Pratta
  • BIOMARKERS FOR GRAFT-VERSUS-HOST DISEASE
    Publication number: 20210123931
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.
    Type: Application
    Filed: October 8, 2020
    Publication date: April 29, 2021
    Inventors: Michael D. Howell, Sherry Owens, Michael A. Pratta
  • BIOMARKERS FOR GRAFT-VERSUS-HOST DISEASE
    Publication number: 20190331697
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.
    Type: Application
    Filed: April 11, 2019
    Publication date: October 31, 2019
    Inventors: Michael D. Howell, Hao Liu, Michael A. Pratta
  • ST2L antagonists and methods of use
    Patent number: 10450377
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: October 22, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiun Wu
  • ST2L ANTAGONISTS AND METHODS OF USE
    Publication number: 20190062439
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Application
    Filed: March 15, 2018
    Publication date: February 28, 2019
    Inventors: Karen DUFFY, Natalie Pursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiun Wu
  • ST2L antagonists and methods of use
    Patent number: 9951137
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: April 24, 2018
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiun Wu
  • ST2L Antagonists and Methods of Use
    Publication number: 20170066831
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Application
    Filed: November 12, 2015
    Publication date: March 9, 2017
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiun Wu
  • ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
    Patent number: 9212227
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: December 15, 2015
    Assignee: Janssen Biotech, Inc.
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiun Wu
  • ST2L antibody antagonists
    Patent number: 9090694
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: July 28, 2015
    Assignee: Janssen Biotech, Inc.
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiun Wu
  • ST2L Antagonists and Methods of Use
    Publication number: 20130336980
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Application
    Filed: March 13, 2013
    Publication date: December 19, 2013
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiu Wu
  • ST2L Antagonists and Methods of Use
    Publication number: 20130287777
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Application
    Filed: March 13, 2013
    Publication date: October 31, 2013
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiu Wu
  • Method for Activating Trpv4 Channel Receptors by Agonists
    Publication number: 20070259856
    Abstract: This invention relates to methods for activating a TRPV4 channel receptor, thereby reducing the production and/or release of matrix degrading enzymes by a cell expressing a TRPV4 channel receptor, thereby reducing the breakdown of an extra-cellular matrix. Also contemplated within the scope of the invention are methods of attenuating the inhibition of matrix production.
    Type: Application
    Filed: September 7, 2005
    Publication date: November 8, 2007
    Inventors: Sanjay Kumar, Michael Pratta, Bartholomew Votta
  • ASSAYS AND PEPTIDE SUBSTRATE FOR DETERMINING AGGRECAN DEGRADING METALLO PROTEASE ACTIVITY
    Publication number: 20070238136
    Abstract: This invention is directed to assays to determine the presence or absence of proteins that exhibit aggrecanase or ADMP activity. This invention also relates to peptides that acts as a substrates for ADMPs, their use in various assays to determine the presence or absence of ADMP activity, and their use as inhibitors of ADMP activity.
    Type: Application
    Filed: April 10, 2007
    Publication date: October 11, 2007
    Inventors: Jeffrey Miller, Elizabeth Arner, Robert Copeland, Gary Davis, Ruiqin Liu, Michael Pratta, Micky Tortorella
  • Assays and peptide substrate for determining aggrecan degrading metallo protease activity
    Patent number: 7223834
    Abstract: This invention is directed to assays to determine the presence or absence of proteins that exhibit aggrecanase or ADMP activity. This invention also relates to peptides that acts as a substrates for ADMPs, their use in various assays to determine the presence or absence of ADMP activity, and their use as inhibitors of ADMP activity.
    Type: Grant
    Filed: October 12, 2001
    Date of Patent: May 29, 2007
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Jeffrey A. Miller, Elizabeth C. Arner, Robert A. Copeland, Gary L. Davis, Ruiqin Liu, Michael A. Pratta, Micky D. Tortorella
  • Antibodies to aggrecan-degrading metalloprotease and diagnostic methods using same
    Patent number: 7049412
    Abstract: The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu373-Ala374. The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.
    Type: Grant
    Filed: August 9, 2000
    Date of Patent: May 23, 2006
    Assignee: Bristol-Myers Squibb Pharma Comp.
    Inventors: Elizabeth C. Arner, Timothy C. Burn, Robert A. Copeland, Carl P. Decicco, Ruiqin Liu, Ronald Magolda, Michael Pratta, Kimberly A. Solomon, Micky D. Tortorella, James M. Trzaskos, Fude Yang
  • Aggrecan degrading metallo proteases
    Patent number: 6753176
    Abstract: The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu373-Ala374. The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.
    Type: Grant
    Filed: September 19, 2002
    Date of Patent: June 22, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Elizabeth C. Arner, Timothy C. Burn, Robert A. Copeland, Carl P. Decicco, Ruiqin Liu, Ronald Magolda, Michael Pratta, Kimberly A. Solomon, Micky D. Tortorella, James M. Trzaskos, Fude Yang
  • Aggrecan degrading metallo proteases
    Publication number: 20030108998
    Abstract: The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu373-Ala374. The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.
    Type: Application
    Filed: September 19, 2002
    Publication date: June 12, 2003
    Inventors: Elizabeth C. Arner, Timothy C. Burn, Robert A. Copeland, Carl P. Decicco, Ruiqin Liu, Ronald Magolda, Michael Pratta, Kimberly A. Solomon, Micky D. Tortorella, James M. Trzaskos, Fude Yang
  • Nucleic acids encoding aggrecan degrading metallo proteases
    Patent number: 6521436
    Abstract: The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu373-Ala374. The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.
    Type: Grant
    Filed: August 9, 2000
    Date of Patent: February 18, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Elizabeth C. Arner, Timothy C. Burn, Robert A. Copeland, Carl P. Decicco, Ruiqin Liu, Ronald Magolda, Michael Pratta, Kimberly A. Solomon, Micky D. Tortorella, James M. Trzaskos, Fude Yang